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Background. The serine/threonine kinase Aurora-A (Aur-A) is a proto-oncoprotein overexpressed in a wide range of human
cancers. Overexpression of Aur-A is thought to be caused by gene amplification or mRNA overexpression. However, recent
evidence revealed that the discrepancies between amplification of Aur-A and overexpression rates of Aur-A mRNA were
observed in breast cancer, gastric cancer, hepatocellular carcinoma, and ovarian cancer. We found that aggressive head and
neck cancers exhibited overexpression and stabilization of Aur-A protein without gene amplification or mRNA overexpression.
Here we tested the hypothesis that aberration of the protein destruction system induces accumulation and consequently
overexpression of Aur-A in cancer. Principal Findings. Aur-A protein was ubiquitinylated by APCCdh1 and consequently
degraded when cells exited mitosis, and phosphorylation of Aur-A on Ser51 was observed during mitosis. Phosphorylation of
Aur-A on Ser51 inhibited its APCCdh1-mediated ubiquitylation and consequent degradation. Interestingly, constitutive
phosphorylation on Ser51 was observed in head and neck cancer cells with protein overexpression and stabilization. Indeed,
phosphorylation on Ser51 was observed in head and neck cancer tissues with Aur-A protein overexpression. Moreover, an Aur-
A Ser51 phospho-mimetic mutant displayed stabilization of protein during cell cycle progression and enhanced ability to cell
transformation. Conclusions/Significance. Broadly, this study identifies a new mode of Aur-A overexpression in cancer
through phosphorylation-dependent inhibition of its proteolysis in addition to gene amplification and mRNA overexpression.
We suggest that the inhibition of Aur-A phosphorylation can represent a novel way to decrease Aur-A levels in cancer therapy.
Citation: Kitajima S, Kudo Y, Ogawa I, Tatsuka M, Kawai H, et al (2007) Constitutive Phosphorylation of Aurora-A on Ser51 Induces Its Stabilization and
Consequent Overexpression in Cancer. PLoS ONE 2(9): e944. doi:10.1371/journal.pone.0000944
INTRODUCTION
A series of periodic kinase reactions by cyclin-dependent kinases
(CDKs) promote the progression of cell cycle [1]. Mitotic events
with drastic and rapid morphological changes are also tightly
regulated by other kinases including Aurora-A, -B and -C [2]. The
serine/threonine kinase Aurora-A (Aur-A) is essential for mitotic
entry, centrosome duplication, spindle formation, chromosome
segregation and cytokinesis [3]. Human Aur-A/STK15 is located at
chromosome 20q13.2, which is commonly amplified in various
cancers, including breast, colon, bladder, ovarian, pancreatic and
head and neck cancers [4–9], and the levels of Aur-A mRNA and
protein are also increased in those tumors [10–14]. Thus,
overexpression of Aur-A kinase activity has been thought to
promote carcinogenesis by disturbing the mechanism which
ensures maintenance of the normal centrosome or chromosome
number, perhaps due to impairment of centrosome or centromere
function, cytokinesis, or spindle checkpoint regulation [2,15,16].
It is well established that most cell cycle regulators are degraded
by the ubiquitin-proteasome system (UPS) [1,17]. Aur-A is also
degraded via the ubiquitin ligase APC (the anaphase-promoting
complex) and its co-activator Cdh1 is involved [18,19]. Proposed
requirements for Aur-A ubiquitylation are recognition of the C-
terminal Destruction box (D-box) by Cdh1 [20] and an additional
A-box/DAD motif in Xenopus Aur-A [21,22]. Furthermore, it has
been suggested that Ser53 (equivalent to Ser51 in human Aur-A)
of the A-box is phosphorylated during mitosis and that
phosphorylation on Ser53 (or 51 in human) is essential for the
mitotic stabilization of Xenopus [23] and human Aur-A [24].
Although the mitotic modification that affects Aur-A stabilization
was discovered, the physiological dynamics and its regulation
remains incompletely understood.
Previous studies have indicated that the level of Aur-A protein in
tumors does not always correlate with amplification of the Aur-A gene
[25,26]. We also found that head and neck cancer cell lines without
gene amplification expressed Aur-A protein at higher levels in
comparison with those with gene amplification. In addition, a recent
study using a transgenic model and derived cells has demonstrated
that transgenic Aur-A protein is protected by UPS-mediated
degradation during mitosis [27]. These cumulative findings led us
to hypothesize that aberration of the protein destruction system
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induces accumulation and consequently overexpression of Aur-A in
cancer. Here, we show that increased levels of Aur-A observed in
head and neck cancer cell lines arise from constitutive phosphory-
lation of Ser51 which prevents the APCCdh1-mediated ubiquitylation
and sequential degradation of Aur-A.
RESULTS
Overexpression of Aur-A in head and neck cancer
correlates with a decrease in its degradation
Overexpression of Aur-A is shown in a wide range of human
cancers. By immunohistochemistry, head and neck cancer cells
expressed Aur-A at higher levels, in comparison with normal oral
epithelial cells (Figure 1A). Importantly, Aur-A overexpression
correlated with poor survival of head and neck cancer patients
(supplementary table, Table S1). As Aur-A is mapped to
chromosome 20q13.2, which is a region commonly amplified in
epithelial malignancies, overexpression of Aur-A is thought to be
caused by gene amplification and/or overexpression of mRNA.
However, we found that high expression of Aur-A protein was not
caused only by gene amplification and mRNA expression in head
and neck cancer cell lines (Figure 1B). In particular, Aur-A protein
expression in HSC2 and HSC3 cells was higher than in HSC4 cells
that contain both gene amplification and elevated mRNA levels.
Treatment with proteasome inhibitor, ZLLL, induced Aur-A protein
accumulation in HSC4 and Ca9-22 cells, but not in those cell lines
Figure 1. Aur-A overexpression in head and neck cancer may be caused by the abnormality of degradation. A: Immunohistochemical expression
of Aur-A is shown in normal oral mucosa and head and neck cancer. B: Comparison of gene amplification, mRNA expression and protein expression in
6 head and neck cancer cell lines. Gene amplification and mRNA expression were previously examined (9). Protein expression was examined by
Western blot analysis. Cul1 expression was used as a loading control. C: Accumulation of Aur-A protein by proteasome inhibitor, ZLLL. Cancer cells
were treated with or without 25 mM ZLLL for 6 h. Expression of Aur-A was examined by Western blot analysis. Cul1 expression was used as a loading
control. D: Half-life of Aur-A in cancer cells. Cancer cells were treated with CHX for indicated time. Expression of Aur-A was examined by Western blot
analysis. Time zeros were normalized for equal amounts of Aur-A rather than equal amount of protein extracts to directly compare the two half-lives.
Cul1 expression was used as a loading control.
doi:10.1371/journal.pone.0000944.g001
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that display high expression of Aur-A (HSC2, HSC3 and Ho-1-U-1)
(Figure 1C). Moreover, the half-life of Aur-A protein was longer in
HSC2 and HSC3 cells than in HSC4 cells correlating with
overexpressed Aur-A protein (Figure 1D). These findings led us to
the hypothesis that, in addition to gene amplification or mRNA
overexpression, Aur-A overexpression in head and neck cancer cells
may be caused by decreased protein degradation.
Phosphorylation of Aur-A on Ser51 inhibits
APCCdh1-mediated degradation
Aur-A protein expression peaks during mitosis in mammalian cells
(supplementary figure, Fig. S1 A and B). ZLLL treatment induced
Aur-A accumulation in cells in G1 phase, but not in cells in mitosis
(supplementary figure, Fig. S1C). In fact, the protein level of Aur-
A decreases in late mitosis as a consequence of ubiquitylation
mediated by APC and its co-activator Cdh1 [20]. Using co-
transfection experiments, we found that Aur-A protein was
degraded via Cdh1, but not Cdc20 (Figure 2A), as previously
reported [18,19,23,24,28]. In contrast, Aur-B, an Aur-A paralog,
was not degraded by either transfection of Cdh1 or Cdc20
(Figure 2A). Next, we examined the detailed mechanism of
APCCdh1-mediated Aur-A degradation. Aur-A has four putative
D-Box and one KEN box motifs, which could potentially be
recognized by the APCCdh1 ubiquitin ligase complex. In Xenopus,
the N-terminus A-box and C-terminus D-box of Aur-A are
essential for its degradation [23]. Schematic domain structure of
human Aur-A wild type and two deletion mutants (DN and DC)
Figure 2. Phosphorylation on Ser51 inhibits APCCdh1-mediated degradation. A: FLAG-tagged Aur-A and Xpress-tagged Aur-B were co-transfected
with or without HA-tagged Cdc20 or Cdh1 in 293T cell. B: Schematic domain structure of Aur-A wild type (wt) and two deletion mutants (DN and DC)
are shown. The position of two degradation motifs, A-box and D-box, are indicated. C: Aur-A-DN or -DC mutant was co-transfected with Cdh1 in 293T
cell. D: A-box mutated (46RVL48 -.AVA) or D-box mutant (371RPML374 -.APMA) Aur-A was co-transfected with or without Cdh1. E: Ser51 was replaced
by alanine (S51A) or aspartic acid (S51D). Each wt, S51A and S51D mutant Aur-A was co-transfected with or without Cdh1 or Cdc20. F: Sensitivity of
ubiquitylation of Aur-A wt and S51 mutants were assayed in vitro. APC immunoprecipitated with anti-Cdc27 antibody from the HeLa cell lysates was
subjected to the in vitro ubiquitylation assay as described in Materials and methods. The reaction was terminated at 60 min. IVT-Aur-A (arrow) was
used as a substrate. ‘‘Aur-AUb’’ indicates ubiquitylated Aur-A.
doi:10.1371/journal.pone.0000944.g002
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are shown in Figure 2B. The position of two degradation motifs,
A-box and D-box, are also indicated. Wild type Aur-A was
degraded by co-transfection of Cdh1, while both DN and DC Aur-
A mutants were not degraded (Figure 2C). The C-terminus D-box
mutant and A-box mutant were also not degraded, indicating that,
similarly to Xenopus, the A-box and D-box motifs are essential for
the degradation of human Aur-A protein (Figure 2D).
It has been reported that Ser53, Thr295 and Ser349 of Aur-A
are phosphorylated in Xenopus mitotic extracts [21]. Interestingly,
phosphorylated Ser53 in Xenopus Aur-A blocks degradation by the
UPS [23]. We generated a phosphorylation defective Aur-A
mutant (Ser51 replaced by Ala; S51A) and a phospho-mimicking
mutant (Ser51 replaced by Asp; S51D). Each mutant was
transfected in cells with or without Cdh1 or Cdc20. Wild type
and S51A mutant were almost completely degraded, when
cotransfected with Cdh1, whereas the S51D mutant was degraded
at a lesser extent (Figure 2E). Wild type, S51A and S51D mutants
were not degraded via APCCdc20 (Figure 2E). According to what
found in vivo, the S51D mutant was less ubiquitylated in vitro by
APCCdh1 (Figure 2F). Overall, these results indicate that
phosphorylation on Ser51 inhibits the D-box-dependent degrada-
tion of Aur-A occurring in G1 cells via APCCdh1.
Aurora-B (Aur-B), a paralogue of Aur-A, differs in localization
and timing of activation during cell cycle from Aur-A, despite the
,60% sequence identity between them. Comparison of the
schematic structure between Aur-A and -B is shown in Figure 3A.
In Similarly to Aur-A, Aur-B has one putative KEN box, four D-
box and one A-box motifs. As shown in Figure 2A, however, Aur-
B was not degraded by the co-expression of either Cdh1 or Cdc20.
The alignment corresponding to the A-box motif of Aur-A and -B
is shown in Figure 3B. Ser51 in Aur-A corresponds to Glu32 in
Aur-B. We thought that Aur-B might not be degraded via
APCCdh1 because of Glu32 mimicking phosphorylation. To
support this hypothesis, the amino acids of the Aur-B A-box were
mutated (KEP -.PSN, ASN, PSA, KSP, KAP and PEN) and then
transfected in cells with or without Cdh1 (Figure 3C). The
schematic of the sites mutated and the results of the co-transfection
experiments are shown in Figure 3D. Interestingly, PSN, ASN,
PSA, KSP and KAP mutants were degraded, while PEN mutant
was not degraded via APCCdh1. Thus, Aur-B appears to be
protected from APCCdh1-mediated degradation because of Glu32
that mimics the effect of phosphorylation. All together, these
results suggest that phosphorylation of Aur-A on Ser51 plays an
important role for the regulation of its stability.
Next, we examined if phosphorylation on Ser51 was involved in
regulation of Aur-A expression during cell cycle progression. We
raised a phospho-specific antibody against a synthetic peptide that
spans the phosphorylated Ser51 residue of Aur-A. This antibody
specifically recognized wild type and S51D mutant, but not S51A
mutant (Figure 4A), indicating that S51D substitution effectively
mimic the negative charge of the phosphate in position 51.
Phosphorylation on Ser51 in endogenous Aur-A was detected in
HeLa cells treated with nocodazole (which increases the percentage
of cells in mitosis), but not in those without nocodazole (Figure 4B).
Ninety minutes after release from mitosis, Aur-A phosphorylated on
Ser51 disappeared with decreasing protein level of Aur-A and
phosphorylated Aur-A on T288 (Figure 4C). Interestingly, phos-
phorylation on Ser51 was not found in cells transfected with a kinase
inactive mutant (K/R; K162R) (Figure 4D). In Fig. 4E, increased
Ser51 phosphorylated Aur-A wt was observed after noc/OA
treatment, whereas FLAG-Aur-A K/R mutant was not observed
with or without noc/OA treatment. We used okadaic acid as
a phosphatase inhibitor. We also used nocodazole for synchronizing
the cells in mitosis when Ser51 is phosphorylated. These results
indicated that the kinase activity of Aur-A is essential for
phosphorylation of Ser51. The finding that Ser51 phosphorylated
Aur-A was increased by noc/OA treatment is strongly supported by
the recent finding that phosphorylation on Ser51 was depho-
sphorytated by PP2A. However, the detailed mechanism of
phosphorylation on Ser51 needs further experiments.
Aur-A overexpression in head and neck cancer cells
is caused by constitutive phosphorylation on Ser51
In consideration of the above findings, we hypothesized that Aur-
A overexpression in head and neck cancer cells may be caused by
stabilization of Aur-A protein through a constitutive phosphory-
lation on Ser51. Therefore, we examined the status of phosphor-
ylation on Ser51 in head and neck cancer cell lines. Phosphor-
ylation on Ser51 was detected in HSC2, HSC3 and Ho-1-U-1 cells
(Figure 5A). Interestingly, these cells expressed Aur-A protein at
higher levels. However, HSC2 and HSC3 cells showed no gene
amplification or mRNA overexpression. HSC4 cells, which display
both gene amplification and high levels of mRNA, but protein
levels lower than that present in HSC2 and HSC3, showed no
phosphorylation on Ser51. Therefore, the status of Ser51 status
appears to affect to protein expression levels. Interestingly,
phosphorylation on Ser51 was also detected in HSC2, HSC3
and Ho-1-U-1 cells when the cells synchronized at G1 phase,
suggesting that Ser51 was constitutively phosphorylated in cancer
cells (Figure 5B). Moreover, we examined the status of phos-
phorylation on Ser51 in head and neck cancer cases. In fact,
phosphorylation on Ser51 was detected in 4 of 9 head and neck
cancer cases (Figure 5C). All cases with phosphorylation on Ser51
showed highly expression of Aur-A protein.
Constitutive phosphorylation on Ser51 enhanced
cell transformation
In order to further assess the tumorigenesis induced by over-
expression of Aur-A protein due to phosphorylation on Ser51, we
performed the stability of S51D mutant and cell transformation in
comparison with wild type. While the expression of the wild type
protein and the S51D mutant is virtually identical in mitotic cells,
the S51D mutant was not degraded when cells exited mitosis
(Figure 6A). In addition, the half-lives of the S51D mutant was
longer than those of the wild type, S51A and K/R mutants
(Figure 6B). Thus, S51D mutant was stably expressed during cell
cycle progression. Then, we examined the effect of cell trans-
formation using BALB/c 3T3 A31-1-1 cells (Figure 6C). We co-
transfected Aur-A and G12V-HRAS (T24-ras), and observed that
Aur-A potentiated the frequency of G12V-HRAS-induced trans-
formation. Interestingly, a much larger number of foci were found
using the S51D mutant, suggesting that constitutive phosphory-
lation on Ser51 has enhanced oncogenic potentials.
DISCUSSION
Aur-A kinase is associated with the centrosome from the time of
centrosome duplication through to mitotic exit, and is also
associated with regions of microtubules proximal to centrosomes
in mitosis [2]. In somatic cells, both the protein levels and the
kinase activity of Aur-A peak during mitosis, and then fall
(supplemental figure, Fig S1) [4,29]. It has been revealed that
Aur-A is ubiquitylated by APCCdh1 at the exit of mitosis
[18,19,23,24,28]. The APCCdh1 ubiquitin ligase complex recog-
nizes proteins containing either D-Box or KEN-box motifs
[30–32]. In fact, Aur-A has four D-Box and one KEN-box motifs.
Here, we confirmed that the C-terminal D-box and N-terminal
Aur-A Stabilization in Cancer
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A-box (47RxLxPSN52) were essential for the degradation of human
Aur-A, in similar to previous reports [20–22]. Moreover, Xenopus
Ser53 within the A-box is phosphorylated during mitosis and that
phosphorylated Ser53 (or 51 in human) is essential for mitotic
specific stabilization [23,24]. We also found that Ser51 phos-
phorylation inhibited APCCdh1-mediated degradation. As shown
in Figure 3A, Aur-B also has four D-Box, one KEN-box motifs
and similar A-box sequences to Aur-A. Although it has recently
been reported that protein level of Aur-B is also controlled by
APCCdh1 [33,34], in our study, Aur-B expression level did not
change after co-transfection with Cdh1 (Figure 2A). Interestingly,
Aur-B E32A and E32S mutants (Glu32 correspond to Ser51 of
Aur-A) were degraded by APCCdh1 (Figure 3C and D), strongly
suggesting that Aur-B may not be degraded because of
Figure 3. Aur-B is not degraded by APCCdh1 through mimicry of phosphorylation at Glu32 in A-box. A: Comparison of schematic structure
between Aur-A and -B is shown. Aur-B has several degradation motifs similarly to Aur-A. B: Corresponding amino acid sequence of A-box between
Aur-A and -B is shown. C: Aur-B with mutated amino acids in A-box (31KEP33 -.PSN, ASN, PSA, KSP, KAP and PEN) was co-transfected with or without
Cdh1. D: Summary of mutated sites and their results are shown.
doi:10.1371/journal.pone.0000944.g003
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phosphorylation mimicking at Glu32. Overall suggest that
phosphorylation on Ser51 plays an important role for stabilization
of Aur-A protein. Interestingly, phosphorylation on Ser51 was not
observed in kinase inactive mutant, suggesting that Ser51
phosphorylation may be regulated at least by Thr288 phosphor-
ylation (Figure 4D and E). Ser51 phosphorylation was observed in
mitosis and disappeared before decreasing protein level of Aur-A
(Figure 4C). Therefore, we suggest that Ser51 phosphorylation
may control the stability of Aur-A protein level and de-
phosphorylation of Ser51 may be a trigger for Aur-A degradation.
Interestingly, it recently has been reported that protein phospha-
tase PP2A and Aur-A are co-localized at the cell poles during
mitosis [35]. We found that Ser51 phosphorylation of Aur-A was
induced after 2h of PP2A inhibitor treatment in HeLa cells (S.
Kitajima and Y. Kudo unpublished data). These findings strongly
suggest that PP2A may control Aur-A degradation by de-
phosphorylating Ser51. Moreover, it is known that defects of
PP2A phosphatase were detected in some cancers and several
PP2A inhibitors can cause malignant alteration [36]. These
findings made us hypothesize that disorder of PP2A may induce
constitutive phosphorylation on Ser51 of Aur-A in cancer cells.
Therefore, we examined the status of PP2A and correlated with
Aur-A Ser51 phosphorylation status in head and neck cancer cell
lines. However, PP2A expression was not correlated with Ser51
phosphorylation status in cancer cell lines (supplementary figure,
Fig. S2). Moreover, we examined the mutation analysis of
PPP2R1B gene, which encodes the beta isoform of the A subunit
of PP2A. PPP2R1B was identified as a putative human tumor
suppressor gene and mutation of PPP2R1B was observed in lung
and colon cancers [37]. We could not observe any mutation of
PPP2R1B gene in head and neck cancer cell lines (data not shown).
Unfortunately, we could not find the possible correlation between
Figure 4. Phosphorylation on Ser51 during mitosis. A: Characterization of phosopho-specific antibody against Ser51 of Aur-A. Expression of Ser51
phosphorylated Aur-A protein is examined by immunoprecipitation (IP) with a phosopho-specific antibody against Ser51 of Aur-A followed by
immunoblottoing (IB) analysis with a monoclonal antibody to Aur-A in wt and S51 mutants of Aur-A transfected 293T cells. B: Phosphorylation of
Ser51 in HeLa cells with or without Noc treatment. C: Phosphorylation on Ser51 in HeLa cells. HeLa cells were released from Noc-induced
prometaphase arrest and collected at the indicated times. Samples were analyzed by SDS-PAGE followed by Western blotting with phospho-S51 Aur-
A, Aur-A, phospho-T288 Aur-A, phospho-histone H3 (Ser10) and Cul1 antibodies (upper panel). Graph shows expression level of Aur-A, phospho-S51
Aur-A, phospho-T288 Aur-A and phospho-histone H3 (Ser10) (lower panel). D: Expression of Ser51 phosphorylated Aur-A protein is examined by
western blot analysis in S51D and K/R (kinase inactive) mutants transfected 293T cells. Phosphorylation on Thr288 was examined to demonstrate that
K/R affected as a dominant negative. E: Expression of Ser51 phosphorylated Aur-A protein is examined by western blot analysis in wt and K/R mutant
transfected 293T cells with nocodazole (noc) and okadaic acid (OA).
doi:10.1371/journal.pone.0000944.g004
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PP2A and Aur-A Ser51 phosphorylation status in cancer. To
demonstrate the correlation between PP2A and Aur-A Ser51
phosphorylation status needs further experiments.
Similarly to Aur-A regulation by phosphorylation, CDC6 is
protected from APC-deirected degradation by virtue of it’s
phosphorylation [38]. Phosphorylated sites of CDC6 by cyclin
E–CDK2 are located directly adjacent to the D-box, and therefore
prevent recognition of CDC6 by APCCdh1. In the case of Aur-A,
Ser51 is located far from the D-box, but Ser51 is located in the A-
box, which is also essential for ubiquitylation. However, S51D
Aur-A mutant as well as wt and S51D mutant can bind to Cdh1
(supplementary figure, Fig. S3A). Surprisingly, Aur-A binds to
Cdh1 and APC component, Cdc27 at M phase (supplementary
figure, Fig. S3B and C). As in vitro ubiquitylation was inhibited in
S51D mutant (Figure 2G), we suggest that Ser51 phosphorylation
may disturb ubiquitylation process by APCCdh1. Although the role
of APC subunits in substrate recognition is more mysterious, not
only the interactions between substrates and co-activators but also
those between substrates and APC seem to be D-box dependent
[39,40]. Mutational analyses have shown that Doc1 is essential for
the capability of APC to ubiquitylate substrates in a processive
manner [41]. Therefore, phosphorylation on Ser51 may disturb
the recognition by APC subunits such as Doc1, but there are
a number of other possibilities. To clarify the mechanism of
protection of Aur-A degradation by phosphorylation on Ser51
further studies will be required. In addition, it is interesting to
examine whether or not regulation of APC mediated proteolysis
by phosphorylation, as found in Aur-A and CDC6, is a common
event among the other substrates.
Aur-A has been reported to be overexpressed in a wide range of
human cancers, and its overexpression induces aneuploidy,
centrosome amplification and tumorigenic transformation in
cultured human and rodent cells [3–5]. As Aur-A is mapped to
chromosome 20q13.2, a region commonly amplified in human
cancers [4–6], overexpression of Aur-A is thought to be caused by
gene amplification or transcriptional activation. In the present
study, we found that high expression of Aur-A protein was not
caused only by gene amplification and mRNA overexpression in
head and neck cancer cell lines. This finding is supported by
previous finding that amplification of Aur-A was detected in only
3% of cases, but more than 60% of cases overexpressed Aur-A
mRNA and protein in hepatocellular carcinomas [42]. Similar
discrepancies between amplification and overexpression rates were
also reported in breast cancer [5], gastric cancer [26] and ovarian
cancer [12]. This discrepancy may be accounted for by our
findings that Ser51 constitutive phosphorylation was observed in
head and neck cancer cells with overexpression of Aur-A protein.
Indeed, Ser51 phosphorylation was also observed in head and
neck cancer tissues with Aur-A protein overexpression. As Ser51
phosphorylation inhibited APCCdh1-mediated degradation, we
strongly suggest that constitutive phosphorylation on Ser51 may
induce protein stabilization and consequent accumulation in
cancer cells that exhibit overexpression of Aur-A protein (Figure 7).
It recently has been revealed that mouse embryonic fibroblasts did
not show the transformed phenotype when Aur-A was over-
expressed [43], and that transgenic mice that overexpress Aur-A
did not develop malignant tumors [44]. Moreover, the corre-
sponding protein was not detected in extracts, in spite of elevated
Figure 5. Aur-A overexpression in head and neck cancer cells is caused by phosphorylation on Ser51. A: Phosphorylation on Ser 51 in head and
neck cancer cells. Expression of Ser51 phosphorylated Aur-A protein is examined by immunoprecipitation (IP) with a phosopho-specific antibody
against Ser51 of Aur-A followed by immunoblottoing (IB) analysis with a monoclonal antibody to Aur-A in head and neck cancer cells. Gene
amplification and mRNA expression were previously examined [9]. B: Constitutive phosphorylation on Ser 51 in head and neck cancer cells. Indicated
cancer cell lines were released from noc-induced prometaphase arrest and collected in 4 h. Cells had almost completely exited from mitosis.
Expression of Ser51 phosphorylated Aur-A protein is examined by immunoprecipitation (IP) with a phosopho-specific antibody against Ser51 of Aur-A
followed by immunoblottoing (IB) analysis with a monoclonal antibody to Aur-A. Cul1 was used as a loading control and phospho-histone H3 (Ser10)
was used as a marker for mitosis. C: Expression of Ser51 phosphorylated Aur-A protein is examined by immunoprecipitation (IP) with a phosopho-
specific antibody against Ser51 of Aur-A followed by immunoblottoing (IB) analysis with a monoclonal antibody to Aur-A in cells in normal oral
mucosal tissue and 9 head and neck cancer tissues. ß-Actin expession was used as a loading control.
doi:10.1371/journal.pone.0000944.g005
Aur-A Stabilization in Cancer
PLoS ONE | www.plosone.org 7 September 2007 | Issue 9 | e944
transcripts for Aur-A in multiple organs of the transgenic mice,
and the treatment of transgenic-derived embryonic fibroblasts with
proteasome inhibitors markedly increased the protein level of
transgenic Aur-A [27]. Therefore, suppression of protein degra-
dation might be important for Aur-A overexpression and its
oncogenic role. Cell transformation by Aur-A overexpression may
require suppression of protein degradation, not additional factors.
Importantly, an Aur-A S51D mutant showed a significantly high
susceptibility to transformation (Figure 6C). In summary, we
suggest that protection of its protein degradation by constitutive
phosphorylation on Ser51 may induce Aur-A overexpression in
cancer, and that non-degradative Aur-A may have strong
oncogenic roles. Therefore, regulation of Aur-A phosphorylation
can be a novel target for cancer therapy.
MATERIALS AND METHODS
Reagents and antibodies
Proteasome inhibitor ZLLL (Z-Leu-Leu-Leu-CHO) was obtained
from Peptide institute inc. (Osaka, Japan). Cycloheximide (CHX),
nocodazole (Noc) and okadaic acid (OA) were obtained from
Sigma. The Aur-A phospho-Ser51-specific antibody was generat-
ed by immunizing rabbits with the synthetic peptide
P*SNSSQRIPC, corresponding to amino acids 50–59 of human
Aur-A sequence with a phospho-Serine at position 51 (*S). The
antibody was purified from serum by two rounds of affinity
chromatography on a phospho-Ser51 peptide column followed by
a non-phosphopeptide column. The polyclonal antibody to cyclin
A has been described previously [45]. Commercial antibodies were
from the following suppliers: polyclonal antibody specific to
phosphorylated Thr288 of Aur-A, Cell Signaling Technology;
anti-p27 mAb, anti-Aur-A mAb and anti-Aur-B mAb, Trans-
duction Laboratories; anti-HA polyclonal Ab (Y-11), Santa-Cruz
Biotechnology; anti-phospho-histone H3 (Ser10) antibody, Up-
state; anti-Cul1 polyclonal antibody, Zymed; anti-FLAG mAb
(M2) and anti-RasVal12 mAb, Sigma; anti-Xpress mAb, Invitro-
gen; anti-a-tubulin mAb, Cedarlane Laboratories.
Tissue samples
Tissue samples of head and neck cancer were retrieved from the
Surgical Pathology Registry of Hiroshima University Hospital
Figure 6. S51D mutant Aur-A enhanced cell transformation in comparison with wild type. A: Alteration of wt and S51D Aur-A expression after
nocodazole release in HeLa cells. HeLa cells were transiently transfected with wt and S51D Aur-A. After 48 h of transfection, cells were synchronized
by noc arrest and mitotic shake-off, released into fresh medium, harvested at the indicated times. Samples were analyzed by SDS-PAGE followed by
Western blotting with FLAG, cyclin-A, p27, phospho-histone H3 (Ser10) and Cul1 antibodies. B: Half-life of wt and mutants (S51A, S51D and KR) of
Aur-A transfected 293T cells (left panel). Cells were treated with CHX for indicated time. Right panel shows Aur-A/Cul1 ratio measured by
densitometry. C: Effect of S51D mutant Aur-A expression on cell transformation in BALB/c 3T3 A31-1-1 cells. FLAG-tagged wt, S51A and S51D mutants
Aur-A were transfected with or without H-Ras (G12V). Expression of wt, S51A and S51D mutants Aurora-A and H-Ras are confirmed by Western blot
analysis (left panel). After 2 weeks of culture, the dishes were fixed with ethanol and stained with Giemsa solution (middle panel). Quantification of
the number of transformed foci as determined using standard criteria (right panel). Error bars represent the s.d.
doi:10.1371/journal.pone.0000944.g006
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from 1998 to 2004 after their written informed consent. 10%
buffered-formalin fixed and paraffin embedded tissues were used
for immunohistochemical examination. The histological grade and
stage of tumor were classified according to the criteria of the Japan
Society for Head and Neck Cancer. For Western blot analysis, 9
head and neck cancer tissues and 1 normal oral mucosal tissue
were obtained from patients underwent surgery at Dental hospital,
Peradeniya, Sri Lanka after their written informed consent. These
tissue specimens were immediately frozen and stored in 280uC.
Informed consent was obtained from all patients for this study.
Our work was approved by the Ethical Committee of Hiroshima
University and Peradeniya University.
Immunohistochemical staining
Immunohistochemical detection of Periostin in head and neck
cancer cases was performed on 4.5 mm sections mounted on
silicon-coated glass slides, using a streptavidin-biotin peroxidase
technique as described previously [46]. The expression of Aur-A
was graded as high (over 30% of tumor cells showed strong or
diffuse immunopositivity) and low (less than 30% of tumor cells
showed week, patchy or focal immunopositivity or no staining).
Three pathologists (Y.K., I.O., and T.T.) made all the assessments.
Plasmid construction and mutagenesis
Human Aur-A cDNA was isolated from the HeLa cDNA library by
RT–PCR using sense and antisense primers. Aur-A cDNA was
then subcloned by insertion into the KpnI/XbaI restriction site of
pcDNA3 with N-terminal FLAG tagging [9]. cDNAs were
subcloned into a pcDNA3.1-His/Xpress vector (Invitrogen).
cDNAs encoding His/Xpress-Aur-B was cloned into pcDNA3.1
[47]. HA-Cdc20 and HA-Cdh1 expression vectors were gift from
Kristian Helin. FLAG-DN and -DC Aur-A mutants were
generated by using restriction enzyme. The pcDNA3 vectors
encoding the FLAG-Aur-A substitution mutants S51A, S51D, A-
box mutant (RVL-.AVA) and D-box mutant (RPML-.APMA)
and the pcDNA3.1 vectors encoding His/Xpress Aur-B sub-
stitution mutants KEP-.PSN, KEP-.PSA, KEP-.KSP, KEP-
.KAP and KEP-.PEN were generated with the use of
a QuickChange site-directed mutagenesis kit (Stratagene).
Cell culture
Six OSCC cell lines (HSC2, HSC3, HSC4, Ca9-22, Ho-1-U-1 and
Ho-1-N-1), HeLa and 293T cells were used. All cell lines were
provided by Japanese Cancer Research Resources Bank. OSCC cell
lines were routinely maintained in RPMI-1640 (Kyokuto Pharma-
ceutical Industrial Co.) supplemented with 10% heat-inactivated
fetal bovine serum (Boehringer Mannheim) and 100 U/ml
penicillin-streptomycin (Gibco) under conditions of 5% CO2 in air
at 37uC. HeLa and 293T cells were routinely maintained in
Dulbecco’s Modified Eagle Medium (DMEM, Nissui Pharmaceu-
tical Co. Ldt.) supplemented with 10% heat-inactivated fetal bovine
serum (Boehringer Mannheim) and 100 U/ml penicillin-streptomy-
cin (Gibco) under conditions of 5% CO2 in air at 37uC. For
experiments, they were grown to subconfluence in this medium.
Transfection, immunoprecipitation, and
immunoblot analysis
293T cells and HeLa were transfected with vectors with the use of
FuGENE6 (Roche). Cell lysis and immunoprecipitation were
performed as described [48]. Thirty mg of protein was subjected to
10% polyacrylamide gel electrophoresis followed by electroblot-
ting onto a nitrocellulose filter. For detection of the immunocom-
plex, the ECL western blotting detection system (Amersham) was
used. The immunoprecipitates were subjected to immunoblot
analysis. For detecting phospho-Ser51 Aur-A, we performed
immunoprecipitation with a phosopho-specific antibody against
Ser51 of Aur-A followed by immunoblottoing analysis with
a monoclonal antibody to Aur-A.
In vitro ubiquitylation assay
[35S] methionine-labeled human Aur-A protein and were prepared
by coupled transcription-translation reactions in rabbit reticulocyte
lysate (Promega). Cold in vitro-translated human Cdh1 protein was
also used. The extracts from HeLa cells were immunoprecipitated
with anti-Cdc27 antibody (Sigma). Immunoprecipitants were in-
cubated with Cdh1 in reaction mixtures contained the following in
a volume of 10 ml: 40 mM Tris-HCl (pH 7.6), 1 mg/ml carboxy-
methyl bovine serum albumin, 1 mM DTT, 5 mM MgCl2, 10 mM
phosphocreatine, 50 mg/ml creatine phosphokinase, 0.5 mM ATP,
50 mM ubiquitin, 1 mM ubiquitin aldehyde, 1 pmol of E1, 5 pmol of
E2-C, 1 mM okadaic acid, 1-2 pmol of [35S] methionine-labeled
human Aur-A protein. Following incubation at 30uC for 1 h, samples
were subjected to electrophoresis on a 10% polyacrylamide-SDS gel.
Transformation
The transformation target BALB/c 3T3 A31-1-1 cells were used in
this study. For detection of oncogenes, exponentially growing cells
(105) were seeded in 60-mm dishes (3 dishes per experiment), after
which the cells were transfected with each expression plasmid using
Lipofectamine (Invitrogen). The expression plasmids for FLAG-
tagged wt and mutants (S51A and S51D) were used. For the positive
control, H-Ras (G12V)-induced transformation, 100 ng of mutated
H-Ras plasmid (G12V; pSV2neo-ras) [49] and 900 ng empty FLAG
vector [9] were mixed together and applied to each dish. After
2 weeks of culture, the dishes were fixed with ethanol and stained
with Geimsa solution (Merck), observed under a dissecting micro-
scope, and judged according to standard criteria [49].
SUPPORTING INFORMATION
Table S1 Summary of Aur-A expression in head and neck
cancer.
Found at: doi:10.1371/journal.pone.0000944.s001 (0.09 MB TIF)
Figure 7. Schematic model of Aur-A overexpression in cancer. During
mitosis, Aur-A is phosphorylated on Ser51 in normal cells. At mitotic
exit, Aur-A is de-phosphorylated by PP2A and ubiquitylated by APCCdh1.
On the other hand, Aur-A is constitutively phosphorylated on Ser51 in
cancer cells. Therefore, Aur-A can not be ubiquitylated and conse-
quently accumulated in cancer cells.
doi:10.1371/journal.pone.0000944.g007
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Figure S1 Cell cycle-dependent regulation of Aur-A protein by
APCCdh1. A: T98G cells were released from serum starvation
and collected at the indicated times. Samples were analyzed by
SDS-PAGE followed by Western blotting with Aur-A, Aur-B,
Cyclin A, Cyclin B, p27, phospho-histone H3 (Ser10) and Cul1
antibodies. Anti-cyclin B antibody was purchased from Trans-
duction Laboratories. B: HeLa cells were released from nocoda-
zole-induced prometaphase arrest and collected at the indicated
times. Samples were analyzed by SDS-PAGE followed by Western
blotting with Aur-A, Aur-B, Cyclin A, Cyclin B, p27, phospho-
histone H3 (Ser10) and Cul1 antibodies. C: Cells at M phase (noc)
and G1 phase (noc+7h) were treated with or without proteasome
inhibitor, ZLLL/MG132. Samples were analyzed by SDS-PAGE
followed by Western blotting with Aur-A, Aur-B, Cyclin A,
phospho-histone H3 (Ser10) and Cul1 antibodies.
Found at: doi:10.1371/journal.pone.0000944.s002 (0.15 MB TIF)
Figure S2 Correlation between the expression of PP2A and Aur-
A Ser51 phosphorylation status. Expression of PP2A (catalytic
subunit alpha) is examined by Western blot analysis. We used an
anti-PP2A (catalytic subunit alpha) monoclonal antibody (Trans-
duction Laboratories). Ser51 phosphorylated Aur-A protein is
examined by immunoprecipitation (IP) with a phosopho-specific
antibody against Ser51 of Aur-A followed by immunoblottoing
(IB) analysis with a monoclonal antibody to Aur-A in head and
neck cancer cells. Gene amplification and mRNA expression were
previously examined [9].
Found at: doi:10.1371/journal.pone.0000944.s003 (0.08 MB TIF)
Figure S3 Aur-A binds to Cdh1 and APC component, cdc27 at
M phase. A: Wild type and mutant (S51A and S51D) Aur-A bind
to Cdh1. Cdh1 was co-transfected with or without Aur-A wt and
two S51 mutants in 293T cell, and then ZLLL was added for 6h
before the cells were collected. Cell extracts were immunopreci-
pitated (IP) with anti-FLAG antibody and immunoblotted with
anti-Cdh1 antibody. Cul1 was used as a loading control. Aur-A wt,
S51A and S51D bind to Cdh1. B: Aur-A binds to Cdh1 at M
phase. After noc treatment, cell extracts were immunoprecipitated
(IP) with anti-Cdh1 antibody and immunoblotted with anti-Aur-A
antibody in HeLa cells. We confirmed the expression of Aur-A,
Cdh1, phospho-histon H3 (P-HH3) and Cul1 in lysates.
Endogenous Aur-A binds to Cdh1 at M phase. C: Aur-A binds
to Cdc27 and Cdh1 at M phase. In HeLa cells at 0h and 9h after
nocodazole (noc) treatment, cell extracts were immunoprecipitated
(IP) with anti-Cdc27 and anti-Cdh1 antibody and immunoblotted
with anti-Aur-A antibody in HeLa cells. Endogenous Aur-A binds
to Cdc27 and Cdh1 at M phase. At G1 phase (noc+9h), these
bindings were not observed.
Found at: doi:10.1371/journal.pone.0000944.s004 (0.10 MB TIF)
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